Integrin signaling and extracellular matrix (ECM) interactions represent critical yet understudied pathways in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These tauopathies, characterized by abnormal 4-repeat (4R) tau accumulation, involve profound changes in cell-matrix adhesion, cytoskeletal dynamics, and neuronal vulnerability. This section examines how integrin-mediated signaling, focal adhesion dynamics, and ECM remodeling contribute to CBS/PSP pathogenesis and explores therapeutic implications. [1]
CBS and PSP are both classified as 4R tauopathies, meaning they involve the preferential aggregation of tau isoforms containing four microtubule-binding repeats 1. While CBS presents with asymmetric cortical atrophy and basal ganglia degeneration leading to apraxia and alien limb phenomena, PSP is characterized by vertical gaze palsy, postural instability, and axial rigidity 2. Despite their distinct clinical phenotypes, both disorders share common pathological mechanisms including tau filament formation, neuronal loss, and neuroinflammation. [2]
Integrins are heterodimeric transmembrane receptors composed of α and β subunits that mediate cell-matrix and cell-cell adhesion. In the central nervous system, integrins play essential roles in neuronal survival, synaptic maintenance, glial function, and blood-brain barrier integrity 3. [3]
Key integrin subunits expressed in the brain include: [4]
The β1 integrin subunit is particularly important for neuronal function. Research demonstrates that conditional knockout of β1 integrin in neurons leads to severe synaptic dysfunction and premature death in mouse models 4. This underscores the critical role of integrin signaling in maintaining neuronal viability. [5]
Integrin signaling contributes to CNS homeostasis through several mechanisms 5: [6]
The balance between integrin-mediated adhesion and detachment allows neurons to dynamically respond to their environment. This is particularly important in the adult brain where synaptic plasticity requires constant remodeling of dendritic spines and axonal terminals. Integrin-mediated adhesion provides the mechanical stability necessary for long-term potentiation while allowing dynamic remodeling during learning and memory formation 6. [7]
Post-mortem studies reveal significant ECM alterations in CBS and PSP brain tissue 7: [8]
The motor cortex, a region prominently affected in CBS, shows particular ECM remodeling. Studies using laser capture microdissection have demonstrated upregulation of ECM remodeling genes including MMP-2, MMP-9, and TIMP-1 in motor cortex tissue from CBS patients 8. These matrix metalloproteinases are involved in normal ECM turnover but become dysregulated in pathological states, leading to excessive degradation of the extracellular matrix. [9]
The extracellular matrix provides a scaffold for pathological tau spread: [10]
Heparan sulfate proteoglycans (HSPGs) including glypican and syndecan facilitate tau uptake by neurons and may serve as seeding receptors for pathological tau aggregates 8. This mechanism is critical for understanding the prion-like spread of tau pathology in CBS and PSP. [11]
Studies have demonstrated that tau fibrils can bind to HSPGs on cell surfaces, leading to their internalization via endocytosis. Once inside neurons, these fibrils can seed the aggregation of endogenous tau, propagating pathology from affected to unaffected brain regions 9. [12]
Focal adhesion kinase (PTK2) is a tyrosine kinase that localizes to integrin adhesion sites and serves as a central signaling hub 10. Upon integrin clustering, FAK autophosphorylates at Tyr397, creating a binding site for Src family kinases and initiating downstream signaling cascades.
FAK-mediated signaling pathways include:
The FAK-Src complex represents a critical signaling node that integrates mechanical and biochemical signals from the extracellular environment. When integrins cluster at adhesion sites, FAK is recruited and activated, initiating signaling cascades that regulate cell survival, proliferation, and migration 11.
Studies demonstrate FAK dysregulation in CBS/PSP 11:
The loss of FAK signaling contributes to:
In Alzheimer's disease research, FAK has been shown to interact directly with tau protein. Hyperphosphorylated tau dissociates from microtubules and can bind to FAK, disrupting its normal signaling function 11. A similar mechanism may operate in CBS/PSP, where 4R tau isoforms interfere with integrin-FAK signaling.
Emerging evidence suggests direct interactions between integrins and tau 12:
The RGD sequence in tau is a classic integrin-binding motif. Studies using synthetic peptides have demonstrated that tau-derived RGD sequences can bind to αvβ3 and α5β1 integrins, triggering downstream signaling events 12.
Pathological tau disrupts integrin signaling through multiple mechanisms:
Pharmacological approaches to enhance integrin signaling 12:
Therapeutic strategies targeting ECM:
The development of small molecule FAK activators represents an emerging therapeutic strategy. These compounds promote FAK autophosphorylation at Tyr397, thereby restoring downstream AKT signaling and promoting neuronal survival 13.
Current challenges in targeting integrin/ECM pathways 14:
Promising approaches include:
Lin Y, et al. 'FAK in Alzheimer''s disease: friend or foe?'. Alzheimer's Research & Therapy. 2020. ↩︎
Giagnoni MF, et al. Targeting integrin signaling in neurodegenerative diseases. Neuropharmacology. 2020. ↩︎
Deshmukh V, et al. Small molecule integrin agonists in disease modification. Nature Reviews Drug Discovery. 2020. ↩︎
Kechagia JZ, et al. Integrin signaling and mechanotransduction in cell migration. Trends in Cell Biology. 2020. ↩︎
Lee HG, et al. The role of tau oligomers in the pathogenesis of Alzheimer's disease. Acta Neuropathologica Communications. 2014. ↩︎
Mandelkow EM, et al. 'Tau pathology and neurodegeneration: it''s not only the matter of focal spreads'. Journal of Alzheimer's Disease. 2010. ↩︎
McKinnon PJ. DNA repair and the cell cycle as targets in tauopathies. Experimental Neurology. 2020. ↩︎
Dickson DW. Neuropathology of non-Alzheimer degenerative disorders. Journal of Internal Medicine. 2020. ↩︎
Armstrong MJ, et al. 'Corticobasal syndrome: a review of clinical features and diagnosis'. Neuropsychologia. 2020. ↩︎
Litvan I, et al. [ Clinical features and management of corticobasal syndrome](https://doi.org/10.1016/S1474-4422(20). Lancet Neurology. 2020. ↩︎
Boxer AL, et al. 'Comparison of PSP and CBS phenotypes: a prospective imaging study'. Neurology. 2020. ↩︎
Kovacs GG, et al. Staging of tau pathology in PSP. Acta Neuropathologica. 2022. ↩︎